On November 6, 2024, Giuseppe Ciaramella, President of Beam Therapeutics Inc (BEAM, Financial), executed a sale of 51,110 shares of the company. Following this transaction, the insider now owns 109,150 shares of Beam Therapeutics Inc. Details of the sale can be found in the SEC Filing.
Beam Therapeutics Inc is a biotechnology company focused on developing precision genetic medicines through base editing. Base editing is a novel approach to gene editing that enables the direct, irreversible conversion of one base pair to another at a targeted genomic location without making a double-stranded break in the DNA.
Over the past year, Giuseppe Ciaramella has sold a total of 106,754 shares and has not made any purchases. The company has seen a total of 16 insider sells and no insider buys during the same period.
On the valuation front, Beam Therapeutics Inc was trading at $26.36 per share on the day of the sale, giving the company a market cap of $2.24 billion. According to the GF Value, the stock has a price-to-GF-Value ratio of 0.31, indicating that it is possibly a value trap and investors should think twice before investing.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might be of interest to current and potential investors trying to understand market sentiment and the financial health of Beam Therapeutics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
